Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company developing novel therapies for ophthalmic diseases,  announced last patient last visit in the phase III study of its lead therapeutic candidate ST-100 (vezocolmitide) for treatment of Dry Eye Disease. Topline data results are expected in February 2025.

"We are pleased to announce the completion of this important milestone for Stuart Therapeutics and offer our congratulations to our study team.  Stuart continues to advance the development of this new drug class for treatment of multiple indications in ophthalmology," said Eric Schlumpf, President & CEO of Stuart.

"We want to express our appreciation to all patient participants, collaborators and investigators, whose contributions enabled the completion of this study.  Our team now shifts its focus to the evaluation of the data to meet our goal of sharing the topline results during the first quarter of 2025."